Elenco degli articoli con argomento «dermatite atopica»

Dermatologia

11 ott 2021

Phase 2a randomized clinical trial of dupilumab

Treatments for alopecia areata (AA) patients with extensive scalp hair loss are limited

05 ott 2021

Improvement in symptoms of anxiety and depression in patients

Improvement in symptoms of anxiety and depression in patients with atopic dermatitis after treatment with baricitinib

05 ott 2021

Feelings of guilt in parents of children with atopic dermatitis

Feelings of guilt may be associated with illness. Patients may feel responsible for their disease

05 lug 2021

The Role of Type 2 Innate Lymphoid Cells in Allergic Diseases

Allergic diseases are significant diseases that affect many patients worldwide.

07 giu 2021

Once-daily upadacitinib versus placebo in adolescents and adults

Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory potency for JAK1 than JAK2, JAK3, and tyrosine kinase 2.

26 apr 2021

Atopic Dermatitis and Infertility

Given that common pathophysiological factors play a role in atopic dermatitis (AD) and infertility

16 apr 2021

Impact of baricitinib in combination with topical steroids

Baricitinib is an oral, selective, reversible Janus kinase 1/2 inhibitor approved in the European Union and Japan and under investigation in the United States for treatment of atopic dermatitis (AD).

29 mar 2021

Tralokinumab for atopic dermatitis

Tralokinumab for atopic dermatitis

23 mar 2021

Biomarkers in atopic dermatitis

Atopic dermatitis (AD) is a common yet complex skin disease, posing a therapeutic challenge with increasingly recognized different phenotypes among variable patient populations.

16 mar 2021

Note informative per i pazienti - vaccini anti SARS-COV-2 in Italia navigation-next-alternate

Vaccini anti SARS-CoV-2 in uso in Italia

04 mar 2021

A 48-week update

A 48-week update of a multicentre real-life experience of dupilumab in adult patients

24 feb 2021

A Short Cycle of Narrow-Band UVB

Since the best clinical response to dupilumab is achieved after 12-16 weeks

15 feb 2021

Skin Barrier Function in Psoriasis and Atopic Dermatitis

Multiple diagnostic tools are used to evaluate psoriasis and atopic dermatitis (AD) severity, but most of them are based on subjective components.

13 gen 2021

Hidradenitis Suppurativa and Atopic Dermatitis: A Two-Way Association

The co-existence of hidradenitis suppurativa (HS) and atopic dermatitis (AD) had been reported but was not investigated in controlled studies.

24 nov 2020

Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib

Atopic dermatitis is a common, chronic, immune-mediated disease associated with several comorbidities.

11 nov 2020

Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis navigation-next-alternate

Real‐world effectiveness and tolerability of dupilumab in adult atopic dermatitis: A single centre, prospective one‐year observational cohort study of the first 100 patients treated

20 ott 2020

Long‐term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients

Dupilumab, an inhibitor of interleukin (IL)‐4/13 activity, is a biological agent approved for the treatment of moderate‐to‐severe atopic dermatitis (AD)

20 ott 2020

Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis

Is exposure to topical calcineurin inhibitors among adult patients with atopic dermatitis associated with increased keratinocyte carcinoma risk?

06 ott 2020

What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice?

A prospective observational study

22 set 2020

Tuscan Consensus on the diagnosis, treatment and follow up of adult atopic dermatitis

Atopic dermatitis (AD) is an inflammatory disease with a chronic-relapsing course that is intensely itchy.